Literature DB >> 24247163

Treatment of smoldering multiple myeloma.

Alessandro Gozzetti1, Marzia Defina, Monica Bocchia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24247163     DOI： 10.1038/nrclinonc.2013.160-c1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

Review 1.  Fluorescence in situ hybridization: uses and limitations.

Authors:  A Gozzetti; M M Le Beau
Journal:  Semin Hematol       Date:  2000-10       Impact factor: 3.851

2.  Haematological cancer: Treatment of smoldering multiple myeloma.

Authors:  S Vincent Rajkumar; Robert A Kyle
Journal:  Nat Rev Clin Oncol       Date:  2013-09-03       Impact factor: 66.675

3.  Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Authors:  María-Victoria Mateos; Miguel-Teodoro Hernández; Pilar Giraldo; Javier de la Rubia; Felipe de Arriba; Lucía López Corral; Laura Rosiñol; Bruno Paiva; Luis Palomera; Joan Bargay; Albert Oriol; Felipe Prosper; Javier López; Eduardo Olavarría; Nuria Quintana; José-Luis García; Joan Bladé; Juan-José Lahuerta; Jesús-F San Miguel
Journal:  N Engl J Med       Date:  2013-08-01       Impact factor: 91.245

4.  Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma.

Authors:  S V Rajkumar; V Gupta; R Fonseca; A Dispenzieri; W I Gonsalves; D Larson; R P Ketterling; J A Lust; R A Kyle; S K Kumar
Journal:  Leukemia       Date:  2013-03-21       Impact factor: 11.528
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.